1. Janux Therapeutics, a clinical-stage biotech company, has seen its stock rise significantly in 2024 due to buyout speculation and promising early-stage trial data. 2. The company focuses on developing oncology therapies using its proprietary Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms. 3. Despite a robust balance sheet and potential large markets, the company's pipeline is early-stage, and there has been significant insider selling.